- In October 2023, Enterome revealed updated results from the Phase 1/2 SPENCER trial, assessing EO2401 combined with nivolumab for the treatment of adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP), two types of adrenal tumors. The trial aims to evaluate the safety and efficacy of this combination therapy. The updated data highlights the potential of EO2401 as a promising treatment option for these challenging, rare cancers.
- In February 2021, Glenmark Pharmaceuticals, a global research-driven company, introduced SUTIB, the generic version of sunitinib oral capsules, in India. This medication is designed to treat kidney cancer and neuroendocrine tumors, offering a more affordable treatment option for patients. The launch reflects Glenmark’s commitment to improving access to essential cancer therapies in emerging markets such as India.
